No Data
Announcement on the 2024 annual results advance of Harbin Pharmaceutical Group Co., Ltd.
Harbin Pharmaceutical Group (600664.SH): The National Medical Products Administration has canceled the drug registration certificate for Phenobarbital Sulfate Tablets, not the 'Xielitping' trademark.
On January 10, Gelonghui reported that Harbin Pharmaceutical Group (600664.SH) issued a clarification notice, addressing media reports claiming that "Xieliting has been 'halted'" and "'Xieliting' has been completely banned from sale," which have drawn the attention of investors and caused a certain degree of misunderstanding, and thus clarification is provided. Recently, the National Medical Products Administration published a notice regarding the cancellation of the registration certificate for Hyoscine butylbromide tablets, halting the production, sale, and use of Hyoscine butylbromide tablets in China, and cancelling the drug registration certificate. Some media reported that "Hyoscine butylbromide tablets are what the public knows as 'Xieliting'." 1. The company segment.
Harbin Pharmaceutical Group (600664.SH): Net income is expected to increase by 38% to 65% year-on-year in 2024.
Gelonghui, January 10th丨Harbin Pharmaceutical Group (600664.SH) announced that, according to preliminary calculations by the financial department, it is expected that the net income attributable to the parent company's owners for the year 2024 will be between 543.97 million yuan and 652.76 million yuan, an increase of 148.71 million yuan to 257.5 million yuan compared to the same period last year, representing a year-on-year increase of 38% to 65%. It is also expected that the net income attributable to the parent company's owners, excluding non-recurring gains and losses, for the year 2024 will be between 517.74 million yuan and 621.28 million yuan, which will increase by 192.42 million yuan to 295.97 million yuan compared to the same period last year.
Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Business And Shares Still Trailing The Market
Harbin Pharmaceutical Group (SHSE:600664) Strong Profits May Be Masking Some Underlying Issues
Report for the third quarter of 2024 of Harbin Pharmaceutical Group Co., Ltd.
Investors Don't See Light At End Of Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Tunnel And Push Stock Down 26%
